Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy
JJ Buggy, L Elias - International reviews of immunology, 2012 - Taylor & Francis
BTK is a kinase that functions downstream of multiple receptors in various hematologic cells.
This review focuses on BTK-dependent pathways that are likely to be involved in …
This review focuses on BTK-dependent pathways that are likely to be involved in …
Latest advances and current challenges in the treatment of multiple myeloma
A Mahindra, J Laubach, N Raje, N Munshi… - Nature reviews Clinical …, 2012 - nature.com
Effectively treating patients with multiple myeloma is challenging. The development of
therapeutic regimens over the past decade that incorporate the proteasome inhibitor …
therapeutic regimens over the past decade that incorporate the proteasome inhibitor …
Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases
J Huang, Z Ma, X Peng, Z Yang, Y Wu… - Journal of Medicinal …, 2024 - ACS Publications
Bruton's tyrosine kinase (BTK) is an attractive target in inflammatory and autoimmune
diseases. However, the effectiveness of BTK inhibitors is limited by side effects and drug …
diseases. However, the effectiveness of BTK inhibitors is limited by side effects and drug …
Emerging biological insights and novel treatment strategies in multiple myeloma
M Gentile, AG Recchia, C Mazzone… - Expert opinion on …, 2012 - Taylor & Francis
Introduction: Survival in multiple myeloma (MM) has improved significantly in the past 10
years due to new treatments, such as thalidomide and lenalidomide (immunomodulatory …
years due to new treatments, such as thalidomide and lenalidomide (immunomodulatory …
[HTML][HTML] Therapeutic strategies for the treatment of multiple myeloma
N Saini, A Mahindra - Discovery medicine, 2013 - discoverymedicine.com
The outcome of patients with myeloma has improved significantly in the past decade with the
incorporation of the immunomodulatory drugs thalidomide and lenalidomide and the …
incorporation of the immunomodulatory drugs thalidomide and lenalidomide and the …
[PDF][PDF] Clinical trials of bisphosphonates in multiple myeloma
A Mahindra, S Pozzi, N Raje - Clin Adv Hematol …, 2012 - hematologyandoncology.net
Multiple myeloma (MM) is a plasma cell disorder characterized by plasma cell infiltration of
the bone marrow (> 10%). In most patients, it is associated with a monoclonal gammopathy …
the bone marrow (> 10%). In most patients, it is associated with a monoclonal gammopathy …